A retrospective assessment of safety, efficacy, and pharmacoeconomics of generic azathioprine in heart-transplant recipients
Although a generic formulation of azathioprine (AZA) has been available since 1996, safety, efficacy and pharmacoeconomic implications following conversion from Imuran (AZA) to generic AZA in heart-transplant patients remains to be determined. A retrospective, safety and efficacy assessment, in addi...
Gespeichert in:
| Veröffentlicht in: | The Journal of heart and lung transplantation 2001-03, Vol.20 (3), p.372-374 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 374 |
|---|---|
| container_issue | 3 |
| container_start_page | 372 |
| container_title | The Journal of heart and lung transplantation |
| container_volume | 20 |
| creator | Haroldson, Jeffrey A Somerville, K.Troy Carlson, Scot Hanson, Julie Emery, Robert W Lake, Kathleen D |
| description | Although a generic formulation of azathioprine (AZA) has been available since 1996, safety, efficacy and pharmacoeconomic implications following conversion from Imuran (AZA) to generic AZA in heart-transplant patients remains to be determined. A retrospective, safety and efficacy assessment, in addition to a cost comparison, was performed in 30 heart-transplant patients who had been switched from Imuran to generic AZA. In heart-transplant patients converted from Imuran to generic AZA, no compromise in safety and efficacy, as measured by white blood cell (WBC) count, infections, rejections, malignancies, and hospitalizations was observed. Generic substitution of Imuran results in an annual cost savings of $318 per patient. |
| doi_str_mv | 10.1016/S1053-2498(00)00170-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76986304</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1053249800001704</els_id><sourcerecordid>76986304</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-4352d08574b7b0011ede0dad0304033e0f8c58697682aea0fca1aa9bc4df68b3</originalsourceid><addsrcrecordid>eNqFkF1rFTEQhoMo9kN_grIgSIWuTnY3-3ElpagVCl7Y-zCbTDyRs5s1k1No8ceb7TnqZa9mLp55Z-YR4pWE9xJk--G7BFWXVTP0ZwDvAGQHZfNEHEulurKWsnua-7_IkThh_gkAVa2q5-JIykp1qlXH4vdFESnFwAuZ5G-pQGZinmhORXAFo6N0d16Qc96gyR3Otlg2GCc0gUyYw-QNr-gPmil6U-A9po0PS_QzFX4uNoQxlSnizMsWc2wk4xefF_AL8czhlunloZ6Km8-fbi6vyutvX75eXlyXpu6HVDb5aAu96pqxG_OnkiyBRQs1NFDXBK43qm-Hru0rJARnUCIOo2msa_uxPhVv97FLDL92xElPng1t8zUUdqy7dujbnJVBtQdNFsKRnM5fTBjvtAS9WtcP1vWqVAPoB-t6nXt9WLAbJ7L_pw6aM_DmACAb3Losw3j-xw1Ktc1KfdxTlF3ceoqaTfZkyPrsLGkb_COH_AG2O6Dd</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76986304</pqid></control><display><type>article</type><title>A retrospective assessment of safety, efficacy, and pharmacoeconomics of generic azathioprine in heart-transplant recipients</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Haroldson, Jeffrey A ; Somerville, K.Troy ; Carlson, Scot ; Hanson, Julie ; Emery, Robert W ; Lake, Kathleen D</creator><creatorcontrib>Haroldson, Jeffrey A ; Somerville, K.Troy ; Carlson, Scot ; Hanson, Julie ; Emery, Robert W ; Lake, Kathleen D</creatorcontrib><description>Although a generic formulation of azathioprine (AZA) has been available since 1996, safety, efficacy and pharmacoeconomic implications following conversion from Imuran (AZA) to generic AZA in heart-transplant patients remains to be determined. A retrospective, safety and efficacy assessment, in addition to a cost comparison, was performed in 30 heart-transplant patients who had been switched from Imuran to generic AZA. In heart-transplant patients converted from Imuran to generic AZA, no compromise in safety and efficacy, as measured by white blood cell (WBC) count, infections, rejections, malignancies, and hospitalizations was observed. Generic substitution of Imuran results in an annual cost savings of $318 per patient.</description><identifier>ISSN: 1053-2498</identifier><identifier>EISSN: 1557-3117</identifier><identifier>DOI: 10.1016/S1053-2498(00)00170-4</identifier><identifier>PMID: 11257565</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adult ; Azathioprine - economics ; Azathioprine - pharmacokinetics ; Azathioprine - therapeutic use ; Biological and medical sciences ; Cost Savings ; Drugs, Generic - economics ; Drugs, Generic - pharmacokinetics ; Drugs, Generic - therapeutic use ; Female ; Heart Transplantation - immunology ; Humans ; Male ; Medical sciences ; Middle Aged ; Minnesota ; Retrospective Studies ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Surgery of the heart</subject><ispartof>The Journal of heart and lung transplantation, 2001-03, Vol.20 (3), p.372-374</ispartof><rights>2001 International Society for Heart and Lung Transplantation</rights><rights>2001 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c389t-4352d08574b7b0011ede0dad0304033e0f8c58697682aea0fca1aa9bc4df68b3</citedby><cites>FETCH-LOGICAL-c389t-4352d08574b7b0011ede0dad0304033e0f8c58697682aea0fca1aa9bc4df68b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1053249800001704$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=955645$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11257565$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Haroldson, Jeffrey A</creatorcontrib><creatorcontrib>Somerville, K.Troy</creatorcontrib><creatorcontrib>Carlson, Scot</creatorcontrib><creatorcontrib>Hanson, Julie</creatorcontrib><creatorcontrib>Emery, Robert W</creatorcontrib><creatorcontrib>Lake, Kathleen D</creatorcontrib><title>A retrospective assessment of safety, efficacy, and pharmacoeconomics of generic azathioprine in heart-transplant recipients</title><title>The Journal of heart and lung transplantation</title><addtitle>J Heart Lung Transplant</addtitle><description>Although a generic formulation of azathioprine (AZA) has been available since 1996, safety, efficacy and pharmacoeconomic implications following conversion from Imuran (AZA) to generic AZA in heart-transplant patients remains to be determined. A retrospective, safety and efficacy assessment, in addition to a cost comparison, was performed in 30 heart-transplant patients who had been switched from Imuran to generic AZA. In heart-transplant patients converted from Imuran to generic AZA, no compromise in safety and efficacy, as measured by white blood cell (WBC) count, infections, rejections, malignancies, and hospitalizations was observed. Generic substitution of Imuran results in an annual cost savings of $318 per patient.</description><subject>Adult</subject><subject>Azathioprine - economics</subject><subject>Azathioprine - pharmacokinetics</subject><subject>Azathioprine - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cost Savings</subject><subject>Drugs, Generic - economics</subject><subject>Drugs, Generic - pharmacokinetics</subject><subject>Drugs, Generic - therapeutic use</subject><subject>Female</subject><subject>Heart Transplantation - immunology</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Minnesota</subject><subject>Retrospective Studies</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Surgery of the heart</subject><issn>1053-2498</issn><issn>1557-3117</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkF1rFTEQhoMo9kN_grIgSIWuTnY3-3ElpagVCl7Y-zCbTDyRs5s1k1No8ceb7TnqZa9mLp55Z-YR4pWE9xJk--G7BFWXVTP0ZwDvAGQHZfNEHEulurKWsnua-7_IkThh_gkAVa2q5-JIykp1qlXH4vdFESnFwAuZ5G-pQGZinmhORXAFo6N0d16Qc96gyR3Otlg2GCc0gUyYw-QNr-gPmil6U-A9po0PS_QzFX4uNoQxlSnizMsWc2wk4xefF_AL8czhlunloZ6Km8-fbi6vyutvX75eXlyXpu6HVDb5aAu96pqxG_OnkiyBRQs1NFDXBK43qm-Hru0rJARnUCIOo2msa_uxPhVv97FLDL92xElPng1t8zUUdqy7dujbnJVBtQdNFsKRnM5fTBjvtAS9WtcP1vWqVAPoB-t6nXt9WLAbJ7L_pw6aM_DmACAb3Losw3j-xw1Ktc1KfdxTlF3ceoqaTfZkyPrsLGkb_COH_AG2O6Dd</recordid><startdate>20010301</startdate><enddate>20010301</enddate><creator>Haroldson, Jeffrey A</creator><creator>Somerville, K.Troy</creator><creator>Carlson, Scot</creator><creator>Hanson, Julie</creator><creator>Emery, Robert W</creator><creator>Lake, Kathleen D</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20010301</creationdate><title>A retrospective assessment of safety, efficacy, and pharmacoeconomics of generic azathioprine in heart-transplant recipients</title><author>Haroldson, Jeffrey A ; Somerville, K.Troy ; Carlson, Scot ; Hanson, Julie ; Emery, Robert W ; Lake, Kathleen D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-4352d08574b7b0011ede0dad0304033e0f8c58697682aea0fca1aa9bc4df68b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adult</topic><topic>Azathioprine - economics</topic><topic>Azathioprine - pharmacokinetics</topic><topic>Azathioprine - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cost Savings</topic><topic>Drugs, Generic - economics</topic><topic>Drugs, Generic - pharmacokinetics</topic><topic>Drugs, Generic - therapeutic use</topic><topic>Female</topic><topic>Heart Transplantation - immunology</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Minnesota</topic><topic>Retrospective Studies</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Surgery of the heart</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Haroldson, Jeffrey A</creatorcontrib><creatorcontrib>Somerville, K.Troy</creatorcontrib><creatorcontrib>Carlson, Scot</creatorcontrib><creatorcontrib>Hanson, Julie</creatorcontrib><creatorcontrib>Emery, Robert W</creatorcontrib><creatorcontrib>Lake, Kathleen D</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of heart and lung transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Haroldson, Jeffrey A</au><au>Somerville, K.Troy</au><au>Carlson, Scot</au><au>Hanson, Julie</au><au>Emery, Robert W</au><au>Lake, Kathleen D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A retrospective assessment of safety, efficacy, and pharmacoeconomics of generic azathioprine in heart-transplant recipients</atitle><jtitle>The Journal of heart and lung transplantation</jtitle><addtitle>J Heart Lung Transplant</addtitle><date>2001-03-01</date><risdate>2001</risdate><volume>20</volume><issue>3</issue><spage>372</spage><epage>374</epage><pages>372-374</pages><issn>1053-2498</issn><eissn>1557-3117</eissn><abstract>Although a generic formulation of azathioprine (AZA) has been available since 1996, safety, efficacy and pharmacoeconomic implications following conversion from Imuran (AZA) to generic AZA in heart-transplant patients remains to be determined. A retrospective, safety and efficacy assessment, in addition to a cost comparison, was performed in 30 heart-transplant patients who had been switched from Imuran to generic AZA. In heart-transplant patients converted from Imuran to generic AZA, no compromise in safety and efficacy, as measured by white blood cell (WBC) count, infections, rejections, malignancies, and hospitalizations was observed. Generic substitution of Imuran results in an annual cost savings of $318 per patient.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>11257565</pmid><doi>10.1016/S1053-2498(00)00170-4</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1053-2498 |
| ispartof | The Journal of heart and lung transplantation, 2001-03, Vol.20 (3), p.372-374 |
| issn | 1053-2498 1557-3117 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_76986304 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Azathioprine - economics Azathioprine - pharmacokinetics Azathioprine - therapeutic use Biological and medical sciences Cost Savings Drugs, Generic - economics Drugs, Generic - pharmacokinetics Drugs, Generic - therapeutic use Female Heart Transplantation - immunology Humans Male Medical sciences Middle Aged Minnesota Retrospective Studies Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Surgery of the heart |
| title | A retrospective assessment of safety, efficacy, and pharmacoeconomics of generic azathioprine in heart-transplant recipients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T02%3A07%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20retrospective%20assessment%20of%20safety,%20efficacy,%20and%20pharmacoeconomics%20of%20generic%20azathioprine%20in%20heart-transplant%20recipients&rft.jtitle=The%20Journal%20of%20heart%20and%20lung%20transplantation&rft.au=Haroldson,%20Jeffrey%20A&rft.date=2001-03-01&rft.volume=20&rft.issue=3&rft.spage=372&rft.epage=374&rft.pages=372-374&rft.issn=1053-2498&rft.eissn=1557-3117&rft_id=info:doi/10.1016/S1053-2498(00)00170-4&rft_dat=%3Cproquest_cross%3E76986304%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76986304&rft_id=info:pmid/11257565&rft_els_id=S1053249800001704&rfr_iscdi=true |